Search

Research

Research in hematology has dramatically improved our understanding of hematologic diseases and resulted in many innovative, groundbreaking discoveries.

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

1st EHA-Balkan Hematology Day

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 1st edition of the EHA-Balkan Hematology Day.

Read more

GoCART Coalition - Call for research proposals within Work Package 6: Scientific Excellence

Dear GoCART community, 

With more than 1500 CAR-T infusions registered in the EBMT registry, EHA and EBMT are proud to announce a series of scientific calls within Work Package 6: Scientific Excellence of the GoCART coalition.

Read more

Report VIRTUAL EHA-SWG Scientific Meeting on Immunotherapy

This scientific meeting was organized together with the EHA Scientific Working Group on Immune Therapies for Hematological Disorders.

Read more

EHA-SWG Scientific Meeting on Red Cell and Iron Metabolism Defects: From Basic Science to Clinical Case Application

Dates: October 12-14, 2023
Location: Budapest, Hungary
Chairs: A Taher & A Iolascon
Collaborating SWG: EHA Specialized Working Group on Red Cells and Iron

 Registration is closed

RegistrationRegistration is closed. Visit this page for more information.

Read more

Program

All session times are in Eastern European Time (EET).

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more